Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2022-11, Vol.140 (Supplement 1), p.1491-1492
Hauptverfasser: Foss, Francine M., Kim, Youn H., Prince, H. Miles Miles, Kuzel, Timothy M., Yannakou, Costas K., Ooi, Chean Eng, Xing, Dongyuan, Sauter, Nicholas, Singh, Preeti, Czuczman, Myron, Duvic, Madeleine
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1492
container_issue Supplement 1
container_start_page 1491
container_title Blood
container_volume 140
creator Foss, Francine M.
Kim, Youn H.
Prince, H. Miles Miles
Kuzel, Timothy M.
Yannakou, Costas K.
Ooi, Chean Eng
Xing, Dongyuan
Sauter, Nicholas
Singh, Preeti
Czuczman, Myron
Duvic, Madeleine
description
doi_str_mv 10.1182/blood-2022-166916
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2022_166916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497122021632</els_id><sourcerecordid>S0006497122021632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1856-1873f87018f880147be7f708163964f72a7c856f5bda3bb0664387bd0eebdc1b3</originalsourceid><addsrcrecordid>eNp9kMFu1DAQQC1EJZbCB_Q2RzgEbGfX9sKpWrYUsaIVXU4Vihx7rBqSOLKdbfNPfGRdljNzmdHMPMvzCDlj9B1jir9vuxBsxSnnFRNizcQzsmArripKOX1OFpRSUS3Xkr0gL1P6RSlb1ny1IH-2znmjzQx6sHCjHeYZgoOtLAFvfD_GcEAL4xR9mXzCwXc4_fYDWO-yz-EBbq--7c-__nwLpXmts8chJ7j3-Q6-Y6fHVOgQS-2iNjnEGTZT1gOGKcG-2mDXwW7ux7vQ6w9lK01dwV0MPVz7Q8i6g5s82Rlqyl-RE6e7hK__5VPy42K731xWu6vPXzbnu8owtRIVU7J2SlKmnFLlUNmidJIqJuq1WDrJtTRlz61aq-u2pUIsayVbSxFba1hbnxJ2fNfEkFJE14zR9zrODaPNk-7mr-7mSXdz1F2Yj0cGy8cOHmOTTFFh0PqIJjc2-P_Qj-JQiSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Foss, Francine M. ; Kim, Youn H. ; Prince, H. Miles Miles ; Kuzel, Timothy M. ; Yannakou, Costas K. ; Ooi, Chean Eng ; Xing, Dongyuan ; Sauter, Nicholas ; Singh, Preeti ; Czuczman, Myron ; Duvic, Madeleine</creator><creatorcontrib>Foss, Francine M. ; Kim, Youn H. ; Prince, H. Miles Miles ; Kuzel, Timothy M. ; Yannakou, Costas K. ; Ooi, Chean Eng ; Xing, Dongyuan ; Sauter, Nicholas ; Singh, Preeti ; Czuczman, Myron ; Duvic, Madeleine</creatorcontrib><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2022-166916</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2022-11, Vol.140 (Supplement 1), p.1491-1492</ispartof><rights>2022 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1856-1873f87018f880147be7f708163964f72a7c856f5bda3bb0664387bd0eebdc1b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Foss, Francine M.</creatorcontrib><creatorcontrib>Kim, Youn H.</creatorcontrib><creatorcontrib>Prince, H. Miles Miles</creatorcontrib><creatorcontrib>Kuzel, Timothy M.</creatorcontrib><creatorcontrib>Yannakou, Costas K.</creatorcontrib><creatorcontrib>Ooi, Chean Eng</creatorcontrib><creatorcontrib>Xing, Dongyuan</creatorcontrib><creatorcontrib>Sauter, Nicholas</creatorcontrib><creatorcontrib>Singh, Preeti</creatorcontrib><creatorcontrib>Czuczman, Myron</creatorcontrib><creatorcontrib>Duvic, Madeleine</creatorcontrib><title>Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302</title><title>Blood</title><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kMFu1DAQQC1EJZbCB_Q2RzgEbGfX9sKpWrYUsaIVXU4Vihx7rBqSOLKdbfNPfGRdljNzmdHMPMvzCDlj9B1jir9vuxBsxSnnFRNizcQzsmArripKOX1OFpRSUS3Xkr0gL1P6RSlb1ny1IH-2znmjzQx6sHCjHeYZgoOtLAFvfD_GcEAL4xR9mXzCwXc4_fYDWO-yz-EBbq--7c-__nwLpXmts8chJ7j3-Q6-Y6fHVOgQS-2iNjnEGTZT1gOGKcG-2mDXwW7ux7vQ6w9lK01dwV0MPVz7Q8i6g5s82Rlqyl-RE6e7hK__5VPy42K731xWu6vPXzbnu8owtRIVU7J2SlKmnFLlUNmidJIqJuq1WDrJtTRlz61aq-u2pUIsayVbSxFba1hbnxJ2fNfEkFJE14zR9zrODaPNk-7mr-7mSXdz1F2Yj0cGy8cOHmOTTFFh0PqIJjc2-P_Qj-JQiSQ</recordid><startdate>20221115</startdate><enddate>20221115</enddate><creator>Foss, Francine M.</creator><creator>Kim, Youn H.</creator><creator>Prince, H. Miles Miles</creator><creator>Kuzel, Timothy M.</creator><creator>Yannakou, Costas K.</creator><creator>Ooi, Chean Eng</creator><creator>Xing, Dongyuan</creator><creator>Sauter, Nicholas</creator><creator>Singh, Preeti</creator><creator>Czuczman, Myron</creator><creator>Duvic, Madeleine</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20221115</creationdate><title>Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302</title><author>Foss, Francine M. ; Kim, Youn H. ; Prince, H. Miles Miles ; Kuzel, Timothy M. ; Yannakou, Costas K. ; Ooi, Chean Eng ; Xing, Dongyuan ; Sauter, Nicholas ; Singh, Preeti ; Czuczman, Myron ; Duvic, Madeleine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1856-1873f87018f880147be7f708163964f72a7c856f5bda3bb0664387bd0eebdc1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Foss, Francine M.</creatorcontrib><creatorcontrib>Kim, Youn H.</creatorcontrib><creatorcontrib>Prince, H. Miles Miles</creatorcontrib><creatorcontrib>Kuzel, Timothy M.</creatorcontrib><creatorcontrib>Yannakou, Costas K.</creatorcontrib><creatorcontrib>Ooi, Chean Eng</creatorcontrib><creatorcontrib>Xing, Dongyuan</creatorcontrib><creatorcontrib>Sauter, Nicholas</creatorcontrib><creatorcontrib>Singh, Preeti</creatorcontrib><creatorcontrib>Czuczman, Myron</creatorcontrib><creatorcontrib>Duvic, Madeleine</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Foss, Francine M.</au><au>Kim, Youn H.</au><au>Prince, H. Miles Miles</au><au>Kuzel, Timothy M.</au><au>Yannakou, Costas K.</au><au>Ooi, Chean Eng</au><au>Xing, Dongyuan</au><au>Sauter, Nicholas</au><au>Singh, Preeti</au><au>Czuczman, Myron</au><au>Duvic, Madeleine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302</atitle><jtitle>Blood</jtitle><date>2022-11-15</date><risdate>2022</risdate><volume>140</volume><issue>Supplement 1</issue><spage>1491</spage><epage>1492</epage><pages>1491-1492</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><pub>Elsevier Inc</pub><doi>10.1182/blood-2022-166916</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2022-11, Vol.140 (Supplement 1), p.1491-1492
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2022_166916
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
title Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T21%3A06%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20Safety%20of%20E7777%20(improved%20purity%20Denileukin%20diftitox%20%5BONTAK%5D)%20in%20Patients%20with%20Relapsed%20or%20Refractory%20Cutaneous%20T-Cell%20Lymphoma:%20Results%20from%20Pivotal%20Study%20302&rft.jtitle=Blood&rft.au=Foss,%20Francine%20M.&rft.date=2022-11-15&rft.volume=140&rft.issue=Supplement%201&rft.spage=1491&rft.epage=1492&rft.pages=1491-1492&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2022-166916&rft_dat=%3Celsevier_cross%3ES0006497122021632%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497122021632&rfr_iscdi=true